Dr. Tage Honoré has been appointed as the Company’s Chairman of the Scientific Advisory Board.
Dr. Honoré is an experienced pharma and biotechnology executive, entrepreneur and pioneer with expert knowledge in the fields of Alzheimer’s disease, amyotrophic lateral sclerosis, anxiety, cancer immunotherapy, chronic pain, depression, epilepsy, female hormone replacement therapy, learning disorders, osteoporosis, Parkinson’s disease, stroke and schizophrenia. His greatest scientific achievement was discovering and naming the AMPA subtype of Excitatory Amino Acid Receptors as well as the AMPA antagonists CNQX and NBQX, which have been key tools for mapping the excitatory pathways in the central nervous system.
Additionally, Dr. Honoré has published more than 100 scientific papers, is inventor on 23 patents and championed 40 drugs to progress from idea to clinical development including three products that entered the prescription drug market. He has held several positions, including: VP Drug Discovery at Novo Nordisk A/S; Senior Executive VP Nervous System Research, Novartis Pharma Inc; VP Discovery Research, Purdue Pharma LP and President and CEO, Aestus Therapeutics Inc.
Dr. Honoré’s successes are attributed to his ability to translate science to product opportunities and his understanding of the need to integrate research, clinic, market and financial stakeholders. The organizational models he developed to obtain record pipeline productivity in several companies are key to his business achievements.
Dr. Honoré has a master’s degree in pharmaceutical science and doctoral degrees in medicinal chemistry and neurobiology, in addition to business training from Harvard Business School and European Management Centre.